News

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially...

August 9, 2012 — The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT study, with the total number of patients randomized...

July 26, 2012 — Transgenomic Inc. has announced that National Government Services, the designated Medicare fiscal intermediary in Connecticut, has confirmed coverage for its proprietary...

July 20, 2012 — Ticagrelor, a blood-thinning drug approved by the U.S. Food and Drug Administration (FDA) in 2011, should be considered along with older blood thinners clopidogrel and prasugrel...

July 20, 2012 — The online clinical drug resource Drugs.com released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood thinners, proton-pump inhibitors, antipsychotics...

Over the past decade there have been several advancements in prothrombin time (PT)/international normalized ration (INR) point-of-care testing (POCT) devices. This is usually performed at an...

June 22, 2012 — The the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for...

June 11, 2012 — Boehringer Ingelheim Pharmaceuticals Inc. announced that the Pradaxa (dabigatran etexilate mesylate) capsules prescribing information has been updated to affirm that "Pradaxa 150...

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents,...

The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients...

May 15, 2012 — Reaching out to patients with a few simple phone calls significantly improves the likelihood they’ll continue to take critically important medication that...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

March 29, 2012 — Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in a specific group of...

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most...

March 8, 2012 — Transgenomic Inc. announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the company’s PGxPredict:...

February 28, 2012 — Janssen Research and Development LLC announced that the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug...

February 23, 2012 — AstraZeneca announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a...

 

January 19, 2012 – New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor can achieve very fast blood thinning effects...

January 9, 2012 – Janssen Research and Development, LLC (JRD) announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA)...

January 5, 2011 – Bayer HealthCare's oral anticoagulant tablet Xarelto (rivaroxaban) has been approved for use in the United Kingdom in two important blood-clotting disorders